BRISBANE, Calif., May 15, 2019 /PRNewswire/
-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic
medicine company, today announced participation in the following
scientific, medical, and investor conferences:
Upcoming Medical & Scientific Conferences
- 2019 World Advanced Therapies and Regenerative Medicine
Congress
"Gene Editing for Therapeutic Applications"
Presentation Date: Friday, May
17th at 3:40 a.m. Eastern
Time
Location: London, United
Kingdom
- Treg Directed Therapies Summit
"Engineering CAR
Regulatory T Cells (CAR-Tregs) for Autoimmunity, Inflammation &
Transplantation"
Presentation Date: Wednesday, May
22nd at 9:30 a.m. Eastern
Time
Location: Boston, MA
- Update on Fabry Disease Meeting
"Liver targeted AAV
gene therapy vectors results in high levels of enzyme activity and
effective substrate reduction in a mouse model of Fabry
disease"
Presentation Date: Sunday, May
26th at 10 a.m. Eastern
Time
Location: Prague, Czech
Republic
- International Society on Thrombosis and Haemostasis
(ISTH) Congress
"Initial results of the Alta study, a
phase 1/2, open label, adaptive, dose-ranging study to assess the
safety and tolerability of SB-525 gene therapy in adult subjects
with severe hemophilia A"
Presentation Date: Saturday, July
6th at 1:00 p.m.
Australian Eastern Standard Time (July
5th at 11 p.m. Eastern
Time)
Location: Melbourne,
Australia
Upcoming Investor Conference
- Jefferies 2019 Healthcare Conference
Presentation
Date: Thursday, June 6th,
at 1:30 p.m. Eastern Time
Location: New York, NY
Members of the Sangamo management team will present a corporate
overview at the Jefferies 2019 Healthcare Conference.
The presentation will be webcast live and may be accessed via
a link on the Sangamo Therapeutics website in the Investors and
Media section under Events and Presentations. The presentation will
be archived on the Sangamo website for two weeks after the
event.
About Sangamo Therapeutics
Sangamo
Therapeutics, Inc. is focused on translating ground-breaking
science into genomic medicines with the potential to transform
patients' lives using gene therapy, ex vivo gene-edited
cell therapy, in vivo genome editing, and gene regulation.
For more information about Sangamo, visit www.sangamo.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-presentations-at-upcoming-scientific-medical-and-investor-conferences-300851021.html
SOURCE Sangamo Therapeutics, Inc.